证券记录 · 已归档季度
EXEL
Exelixis, Inc. · Healthcare · Biotechnology
20被追踪持有人
-1Δ持有人
116.93M持有股份
$4.83B报告持仓市值
+0新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -4.8% ·
股份流向 -1.3% ·
净新建仓位 -10.0%
· 公式
广泛减持：持股数量下降，持有人数量减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 343.80K | $18.50M | n/a | −1 |
| Q2 2026 | 137 | -1 | 179.98M | $9.79B | +5 | −8 |
| Q1 2026 | 143 | -1 | 180.18M | $7.73B | +4 | −6 |
| Q4 2025 | 143 | +1 | 192.52M | $8.44B | +2 | n/a |
| Q3 2025 | 20 | -1 | 116.93M | $4.83B | n/a | −2 |
| Q2 2025 | 19 | +2 | 115.09M | $5.07B | +2 | n/a |
| Q1 2025 | 14 | -1 | 52.64M | $1.94B | +1 | −2 |
| Q4 2024 | 15 | +1 | 49.00M | $1.63B | +1 | n/a |
| Q3 2024 | 13 | 0 | 34.27M | $889.30M | n/a | n/a |
| Q2 2024 | 13 | n/a | 31.74M | $712.85M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 29.37M | -2.3% | $1.21B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (被动) | 26.06M | -5.1% | $1.08B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Renaissance Technologies ✦ | 15.46M | -2.3% | $638.47M | 0.8% | ▼ Trim | 6 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (被动) | 11.11M | -2.4% | $459.04M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 9.18M | +20.7% | $379.19M | 0.2% | ▲ Add | 6 | SEC ↗ ×5 |
| 6 | Geode Capital Management ✦ (被动) | 7.67M | +3.0% | $316.85M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Arrowstreet Capital ✦ | 5.27M | +0.1% | $217.57M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 8 | Morgan Stanley ✦ | 3.21M | n/a | $132.60M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 9 | JPMorgan Chase ✦ | 1.88M | n/a | $77.80M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 10 | Fidelity (FMR) ✦ | 1.79M | -33.9% | $73.74M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 11 | T. Rowe Price ✦ | 1.13M | -22.0% | $46.74M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Millennium Management ✦ | 1.08M | +84.5% | $44.45M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 1.00M | n/a | $41.36M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Bridgewater Associates ✦ | 842.97K | +3940.1% | $34.81M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 834.02K | -1.4% | $34.44M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 640.28K | +409.6% | $26.44M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | D. E. Shaw & Co. ✦ | 225.43K | -62.6% | $9.31M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 18 | Wellington Management ✦ | 88.17K | -10.9% | $3.64M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | Fisher Asset Management ✦ | 46.81K | +4.4% | $1.93M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 39.31K | -93.9% | $1.62M | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Norges Bank | $122.10M | 曾为 0.0% |
| Marshall Wace | $6.95M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 692 持有人, 256.72M 股份, $10.43B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 10
Beckerle Mary C
Director · 9.81K 股 · $526,512
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13D/A: FARALLON CAPITAL MANAGEMENT, L.L.C.
5.6% 占股份类别 · 查看 SEC 原始申报文件 ↗
Aug 12
SC 13G/A: AQR CAPITAL MANAGEMENT LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据